Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Dyslipidemia | Research

Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China

Authors: Yicheng Fang, Wendan Mei, Chenxu Wang, Xia Ren, Jian Hu, Fan Su, Lei Cao, Grace Tavengana, Mingfei Jiang, Huan Wu, Yufeng Wen

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Background

While dyslipidemia has been recognized as a potential risk factor for hyperuricemia, there is currently a dearth of large-scale data specifically focused on studying the relationship between these two conditions. To address this gap, the present study analyzed a dataset of 298,891 physical examination records to investigate in greater detail the clinical classification and compositional relationship between hyperuricemia and dyslipidemia.

Methods

For this investigation, a cross-sectional research design was utilized to analyze physical examination data that was gathered from Yijishan Hospital in Wuhu, China between 2011 and 2016. Logistic regression was employed to examine the association between hyperuricemia and dyslipidemia. Furthermore, the association between hyperuricemia and dyslipidemia was evaluated based on the clinical classifications of dyslipidemia and its components.

Results

A total of 298,891 participants from China (124,886 [41.8%] females) were included in the study, with an age range of 18 to 90 years (mean [SD]: 47.76 [13.54] years). In multivariate analysis, the odds of hyperuricemia was 1.878 times higher in patients with dyslipidemia compared to those without dyslipidemia (95% confidence interval [CI]: 1.835–1.922). In the clinical classification of dyslipidemia, individuals with hypertriglyceridemia and mixed hyperlipidemia had 1.753 times (95% CI: 1.706–1.802) and 1.925 times (95% CI: 1.870–1.982) higher odds of hyperuricemia, respectively, compared to those without dyslipidemia. Among the components of dyslipidemia, the odds ratios for hyperuricemia in individuals in the fourth quartile compared to those in the first quartile were 3.744 (95% CI: 3.636–3.918) for triglycerides, 1.518 (95% CI: 1.471–1.565) for total cholesterol, and 1.775 (95% CI: 1.718 − 1.833) for non-high-density lipoprotein cholesterol.

Conclusions

Dyslipidemia has been independently linked with hyperuricemia. Moreover, the elevation of triglycerides or total cholesterol levels, including conditions such as hypertriglyceridemia and mixed hyperlipidemia, have been observed to have a positive association with the development of hyperuricemia.
Literature
1.
go back to reference Zhang Y, Yu H, Chai S, Chai X, Wang L, Geng WC, Li JJ, Yue YX, Guo DS, Wang Y. Noninvasive and individual-centered monitoring of uric acid for precaution of Hyperuricemia via Optical Supramolecular Sensing. Adv Sci (Weinh). 2022;9:e2104463.CrossRefPubMed Zhang Y, Yu H, Chai S, Chai X, Wang L, Geng WC, Li JJ, Yue YX, Guo DS, Wang Y. Noninvasive and individual-centered monitoring of uric acid for precaution of Hyperuricemia via Optical Supramolecular Sensing. Adv Sci (Weinh). 2022;9:e2104463.CrossRefPubMed
2.
go back to reference Kim SC, Neogi T, Kang EH, Liu J, Desai RJ, Zhang M, Solomon DH. Cardiovascular risks of Probenecid Versus Allopurinol in older patients with gout. J Am Coll Cardiol. 2018;71:994–1004.CrossRefPubMedPubMedCentral Kim SC, Neogi T, Kang EH, Liu J, Desai RJ, Zhang M, Solomon DH. Cardiovascular risks of Probenecid Versus Allopurinol in older patients with gout. J Am Coll Cardiol. 2018;71:994–1004.CrossRefPubMedPubMedCentral
3.
go back to reference Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323–45.CrossRefPubMed Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323–45.CrossRefPubMed
4.
go back to reference Kim Y, Choi JH, Kang J, Kim GT, Lee SG. Associations of serum retinol and alpha-tocopherol levels with uric acid concentrations: analysis of a Population-Based, nationally Representative Sample. Nutrients 2020, 12. Kim Y, Choi JH, Kang J, Kim GT, Lee SG. Associations of serum retinol and alpha-tocopherol levels with uric acid concentrations: analysis of a Population-Based, nationally Representative Sample. Nutrients 2020, 12.
5.
go back to reference Song J, Jin C, Shan Z, Teng W, Li J. Prevalence and risk factors of Hyperuricemia and gout: a cross-sectional survey from 31 provinces in Mainland China. J Transl Int Med. 2022;10:134–45.CrossRefPubMedPubMedCentral Song J, Jin C, Shan Z, Teng W, Li J. Prevalence and risk factors of Hyperuricemia and gout: a cross-sectional survey from 31 provinces in Mainland China. J Transl Int Med. 2022;10:134–45.CrossRefPubMedPubMedCentral
6.
go back to reference Otaki Y, Konta T, Ichikawa K, Fujimoto S, Iseki K, Moriyama T, Yamagata K, Tsuruya K, Narita I, Kondo M, et al. Possible burden of hyperuricaemia on mortality in a community-based population: a large-scale cohort study. Sci Rep. 2021;11:8999.CrossRefPubMedPubMedCentral Otaki Y, Konta T, Ichikawa K, Fujimoto S, Iseki K, Moriyama T, Yamagata K, Tsuruya K, Narita I, Kondo M, et al. Possible burden of hyperuricaemia on mortality in a community-based population: a large-scale cohort study. Sci Rep. 2021;11:8999.CrossRefPubMedPubMedCentral
7.
go back to reference Nakanishi N, Yoshida H, Nakamura K, Suzuki K, Tatara K. Predictors for development of hyperuricemia: an 8-year longitudinal study in middle-aged Japanese men. Metabolism. 2001;50:621–6.CrossRefPubMed Nakanishi N, Yoshida H, Nakamura K, Suzuki K, Tatara K. Predictors for development of hyperuricemia: an 8-year longitudinal study in middle-aged Japanese men. Metabolism. 2001;50:621–6.CrossRefPubMed
8.
go back to reference Gee Teng G, Pan A, Yuan JM, Koh WP. Cigarette Smoking and the risk of incident gout in a prospective cohort study. Arthritis Care Res (Hoboken). 2016;68:1135–42.CrossRefPubMed Gee Teng G, Pan A, Yuan JM, Koh WP. Cigarette Smoking and the risk of incident gout in a prospective cohort study. Arthritis Care Res (Hoboken). 2016;68:1135–42.CrossRefPubMed
9.
go back to reference Hou YL, Yang XL, Wang CX, Zhi LX, Yang MJ, You CG. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019;18:81.CrossRefPubMedPubMedCentral Hou YL, Yang XL, Wang CX, Zhi LX, Yang MJ, You CG. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019;18:81.CrossRefPubMedPubMedCentral
10.
go back to reference Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident Hypertension among men. J Am Soc Nephrol. 2007;18:287–92.CrossRefPubMed Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident Hypertension among men. J Am Soc Nephrol. 2007;18:287–92.CrossRefPubMed
11.
go back to reference Li LX, Dong XH, Li MF, Zhang R, Li TT, Shen J, Shen J, Bao YQ, Jia WP. Serum uric acid levels are associated with Hypertension and metabolic syndrome but not Atherosclerosis in Chinese inpatients with type 2 Diabetes. J Hypertens. 2015;33:482–90. discussion 490.CrossRefPubMedPubMedCentral Li LX, Dong XH, Li MF, Zhang R, Li TT, Shen J, Shen J, Bao YQ, Jia WP. Serum uric acid levels are associated with Hypertension and metabolic syndrome but not Atherosclerosis in Chinese inpatients with type 2 Diabetes. J Hypertens. 2015;33:482–90. discussion 490.CrossRefPubMedPubMedCentral
12.
go back to reference Yang C, Yang S, Feng C, Zhang C, Xu W, Zhang L, Yan Y, Deng J, Ohore OE, Li J. Associations of hyperuricemia and obesity with remission of nonalcoholic fatty Liver Disease among Chinese men: a retrospective cohort study. PLoS ONE. 2018;13:e0192396.CrossRefPubMedPubMedCentral Yang C, Yang S, Feng C, Zhang C, Xu W, Zhang L, Yan Y, Deng J, Ohore OE, Li J. Associations of hyperuricemia and obesity with remission of nonalcoholic fatty Liver Disease among Chinese men: a retrospective cohort study. PLoS ONE. 2018;13:e0192396.CrossRefPubMedPubMedCentral
13.
go back to reference Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18:689–700.CrossRefPubMed Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18:689–700.CrossRefPubMed
14.
go back to reference Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. Metabolism. 2019;92:71–81.CrossRefPubMed Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. Metabolism. 2019;92:71–81.CrossRefPubMed
15.
go back to reference Peng TC, Wang CC, Kao TW, Chan JY, Yang YH, Chang YW, Chen WL. Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int 2015, 2015:127596. Peng TC, Wang CC, Kao TW, Chan JY, Yang YH, Chang YW, Chen WL. Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int 2015, 2015:127596.
16.
go back to reference Liang J, Jiang Y, Huang Y, Song W, Li X, Huang Y, Ou J, Wei Q, Gu J. The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. Lipids Health Dis. 2020;19:31.CrossRefPubMedPubMedCentral Liang J, Jiang Y, Huang Y, Song W, Li X, Huang Y, Ou J, Wei Q, Gu J. The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. Lipids Health Dis. 2020;19:31.CrossRefPubMedPubMedCentral
17.
go back to reference Yu Y, Huang X, Li M, Ding C, Hu L, Zhong X, Zhou W, Wang T, Zhu L, Bao H, Cheng X. Is there a nonlinear relationship between serum uric acid and lipids in a Hypertensive Population with eGFR >/=30 ml/min/1.73 m(2)? Findings from the China Hypertension Registry Study. Int J Endocrinol. 2020;2020:9725979.CrossRefPubMedPubMedCentral Yu Y, Huang X, Li M, Ding C, Hu L, Zhong X, Zhou W, Wang T, Zhu L, Bao H, Cheng X. Is there a nonlinear relationship between serum uric acid and lipids in a Hypertensive Population with eGFR >/=30 ml/min/1.73 m(2)? Findings from the China Hypertension Registry Study. Int J Endocrinol. 2020;2020:9725979.CrossRefPubMedPubMedCentral
18.
go back to reference Tian Y, Chen K, Xie Z, Fang Y, Wang H, Nie Y, Hu D, Mu Y. The association between serum uric acid levels, metabolic syndrome and Cardiovascular Disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study. BMC Cardiovasc Disord. 2015;15:66.CrossRefPubMedPubMedCentral Tian Y, Chen K, Xie Z, Fang Y, Wang H, Nie Y, Hu D, Mu Y. The association between serum uric acid levels, metabolic syndrome and Cardiovascular Disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study. BMC Cardiovasc Disord. 2015;15:66.CrossRefPubMedPubMedCentral
19.
go back to reference Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis. 2005;183:147–55.CrossRefPubMed Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis. 2005;183:147–55.CrossRefPubMed
20.
go back to reference Babio N, Martinez-Gonzalez MA, Estruch R, Warnberg J, Recondo J, Ortega-Calvo M, Serra-Majem L, Corella D, Fito M, Ros E, et al. Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. Nutr Metab Cardiovasc Dis. 2015;25:173–80.CrossRefPubMed Babio N, Martinez-Gonzalez MA, Estruch R, Warnberg J, Recondo J, Ortega-Calvo M, Serra-Majem L, Corella D, Fito M, Ros E, et al. Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. Nutr Metab Cardiovasc Dis. 2015;25:173–80.CrossRefPubMed
21.
go back to reference Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404–10.CrossRefPubMed Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404–10.CrossRefPubMed
22.
go back to reference Kuwabara M. Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse (Basel). 2016;3:242–52.CrossRefPubMed Kuwabara M. Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse (Basel). 2016;3:242–52.CrossRefPubMed
23.
go back to reference Wu J, Qiu L, Cheng XQ, Xu T, Wu W, Zeng XJ, Ye YC, Guo XZ, Cheng Q, Liu Q, et al. Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population. Sci Rep. 2017;7:5456.CrossRefPubMedPubMedCentral Wu J, Qiu L, Cheng XQ, Xu T, Wu W, Zeng XJ, Ye YC, Guo XZ, Cheng Q, Liu Q, et al. Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population. Sci Rep. 2017;7:5456.CrossRefPubMedPubMedCentral
24.
go back to reference Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9:129–69.CrossRefPubMed Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9:129–69.CrossRefPubMed
25.
go back to reference Expert Dyslipidemia P, Grundy SM. An International Atherosclerosis Society Position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7:561–5.CrossRef Expert Dyslipidemia P, Grundy SM. An International Atherosclerosis Society Position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7:561–5.CrossRef
26.
27.
go back to reference Ostchega Y, Hughes JP, Zhang G, Nwankwo T, Graber J, Nguyen DT. Differences in Hypertension prevalence and Hypertension control by urbanization among adults in the United States, 2013–2018. Am J Hypertens. 2022;35:31–41.CrossRefPubMed Ostchega Y, Hughes JP, Zhang G, Nwankwo T, Graber J, Nguyen DT. Differences in Hypertension prevalence and Hypertension control by urbanization among adults in the United States, 2013–2018. Am J Hypertens. 2022;35:31–41.CrossRefPubMed
29.
go back to reference Ali N, Perveen R, Rahman S, Mahmood S, Rahman S, Islam S, Haque T, Sumon AH, Kathak RR, Molla NH, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: a study on Bangladeshi adults. PLoS ONE. 2018;13:e0206850.CrossRefPubMedPubMedCentral Ali N, Perveen R, Rahman S, Mahmood S, Rahman S, Islam S, Haque T, Sumon AH, Kathak RR, Molla NH, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: a study on Bangladeshi adults. PLoS ONE. 2018;13:e0206850.CrossRefPubMedPubMedCentral
30.
go back to reference Zhang Y, Zhang M, Yu X, Wei F, Chen C, Zhang K, Feng S, Wang Y, Li WD. Association of Hypertension and hypertriglyceridemia on incident hyperuricemia: an 8-year prospective cohort study. J Transl Med. 2020;18:409.CrossRefPubMedPubMedCentral Zhang Y, Zhang M, Yu X, Wei F, Chen C, Zhang K, Feng S, Wang Y, Li WD. Association of Hypertension and hypertriglyceridemia on incident hyperuricemia: an 8-year prospective cohort study. J Transl Med. 2020;18:409.CrossRefPubMedPubMedCentral
31.
go back to reference Chen JH, Pan WH, Hsu CC, Yeh WT, Chuang SY, Chen PY, Chen HC, Chang CT, Huang WL. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken). 2013;65:133–40.CrossRefPubMed Chen JH, Pan WH, Hsu CC, Yeh WT, Chuang SY, Chen PY, Chen HC, Chang CT, Huang WL. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken). 2013;65:133–40.CrossRefPubMed
32.
go back to reference Huang XB, Zhang WQ, Tang WW, Liu Y, Ning Y, Huang C, Liu JX, Yi YJ, Xu RH, Wang TD. Prevalence and associated factors of hyperuricemia among urban adults aged 35–79 years in southwestern China: a community-based cross-sectional study. Sci Rep. 2020;10:15683.CrossRefPubMedPubMedCentral Huang XB, Zhang WQ, Tang WW, Liu Y, Ning Y, Huang C, Liu JX, Yi YJ, Xu RH, Wang TD. Prevalence and associated factors of hyperuricemia among urban adults aged 35–79 years in southwestern China: a community-based cross-sectional study. Sci Rep. 2020;10:15683.CrossRefPubMedPubMedCentral
33.
go back to reference Haj Mouhamed D, Ezzaher A, Neffati F, Douki W, Gaha L, Najjar MF. Effect of cigarette Smoking on plasma uric acid concentrations. Environ Health Prev Med. 2011;16:307–12.CrossRefPubMed Haj Mouhamed D, Ezzaher A, Neffati F, Douki W, Gaha L, Najjar MF. Effect of cigarette Smoking on plasma uric acid concentrations. Environ Health Prev Med. 2011;16:307–12.CrossRefPubMed
34.
go back to reference Shirasawa T, Ochiai H, Yoshimoto T, Nagahama S, Watanabe A, Yoshida R, Kokaze A. Cross-sectional study of associations between normal body weight with central obesity and hyperuricemia in Japan. BMC Endocr Disorders 2020, 20. Shirasawa T, Ochiai H, Yoshimoto T, Nagahama S, Watanabe A, Yoshida R, Kokaze A. Cross-sectional study of associations between normal body weight with central obesity and hyperuricemia in Japan. BMC Endocr Disorders 2020, 20.
35.
go back to reference Oku F, Hara A, Tsujiguchi H, Suzuki K, Pham KO, Suzuki F, Miyagi S, Nakamura M, Takazawa C, Sato K et al. Association between Dietary Fat Intake and Hyperuricemia in men with chronic Kidney Disease. Nutrients 2022, 14. Oku F, Hara A, Tsujiguchi H, Suzuki K, Pham KO, Suzuki F, Miyagi S, Nakamura M, Takazawa C, Sato K et al. Association between Dietary Fat Intake and Hyperuricemia in men with chronic Kidney Disease. Nutrients 2022, 14.
36.
go back to reference Deb S, Sakharkar P. A Population based study of liver function amongst adults with hyperuricemia and gout in the United States. Diseases 2021, 9. Deb S, Sakharkar P. A Population based study of liver function amongst adults with hyperuricemia and gout in the United States. Diseases 2021, 9.
38.
go back to reference Yang WX, Ma Y, Hou YL, Wang YB, You CG. Prevalence of Hyperuricemia and its correlation with serum lipids and blood glucose in Physical Examination Population in 2015–2018: a retrospective study. Clin Lab 2019, 65. Yang WX, Ma Y, Hou YL, Wang YB, You CG. Prevalence of Hyperuricemia and its correlation with serum lipids and blood glucose in Physical Examination Population in 2015–2018: a retrospective study. Clin Lab 2019, 65.
39.
go back to reference Zhang Y, Wei F, Chen C, Cai C, Zhang K, Sun N, Tian J, Shi W, Zhang M, Zang Y, et al. Higher triglyceride level predicts hyperuricemia: a prospective study of 6-year follow-up. J Clin Lipidol. 2018;12:185–92.CrossRefPubMed Zhang Y, Wei F, Chen C, Cai C, Zhang K, Sun N, Tian J, Shi W, Zhang M, Zang Y, et al. Higher triglyceride level predicts hyperuricemia: a prospective study of 6-year follow-up. J Clin Lipidol. 2018;12:185–92.CrossRefPubMed
40.
go back to reference Balasubramanian T. Uric acid or 1-methyl uric acid in the urinary bladder increases serum glucose, insulin, true triglyceride, and total cholesterol levels in Wistar rats. ScientificWorldJournal. 2003;3:930–6.CrossRefPubMedPubMedCentral Balasubramanian T. Uric acid or 1-methyl uric acid in the urinary bladder increases serum glucose, insulin, true triglyceride, and total cholesterol levels in Wistar rats. ScientificWorldJournal. 2003;3:930–6.CrossRefPubMedPubMedCentral
41.
go back to reference Furuhashi M. New insights into purine metabolism in metabolic Diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 2020;319:E827–34.CrossRefPubMed Furuhashi M. New insights into purine metabolism in metabolic Diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 2020;319:E827–34.CrossRefPubMed
42.
go back to reference Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338–67.CrossRefPubMed Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338–67.CrossRefPubMed
43.
go back to reference Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, Hermans MP, Pandey RC, Ray KK, Tokgozoglu L, et al. Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook. Atherosclerosis. 2023;383:117312.CrossRefPubMed Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, Hermans MP, Pandey RC, Ray KK, Tokgozoglu L, et al. Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook. Atherosclerosis. 2023;383:117312.CrossRefPubMed
44.
go back to reference Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel m. An International Atherosclerosis Society Position paper: global recommendations for the management of dyslipidemia–full report. J Clin Lipidol. 2014;8:29–60.CrossRef Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel m. An International Atherosclerosis Society Position paper: global recommendations for the management of dyslipidemia–full report. J Clin Lipidol. 2014;8:29–60.CrossRef
Metadata
Title
Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China
Authors
Yicheng Fang
Wendan Mei
Chenxu Wang
Xia Ren
Jian Hu
Fan Su
Lei Cao
Grace Tavengana
Mingfei Jiang
Huan Wu
Yufeng Wen
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Dyslipidemia
Published in
BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01528-7

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.